GPT and Hyperbilirubinemia: Serious adverse events occurred in 38% of participants—most often abdominal pain, transient transaminase elevations (AST 7%, ALT 5%), and hypotension and hyperbilirubinemia (each 5%)—but led to permanent drug discontinuation in only two cases (CRS and abdominal pain).